Skip to content

clinical study for optimized Haplo-Cord mode in pediatric hematopoietic stem cell transplantation

clinical study for optimized Haplo-Cord mode in pediatric hematopoietic stem cell transplantation

Status
Recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029458
Enrollment
Unknown
Registered
2020-02-02
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric hematopoietic stem cell transplantation

Interventions

Sponsors

Children's Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.8 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Aged 1-18 years old; 2. Met the transplantation indications and had the intention of transplantation; 3. Before transplantation, the blood routine, liver and kidney function, complete virus set, HLA antibody screening, ECG, cardiac ultrasound, lung function, lung CT and other examinations were completed, excluding the contraindications for transplantation; 4. Before transplantation, allo-HSCT was not accepted; Criteria for cord blood screening: 8 cord blood banks across China inquired for the right cord blood, expanded the scope of screening in order to find more satisfactory cord blood; according to the HLA antibody screening results, DSA positive cord blood was eliminated; HLA matching was the priority factor, and HLA >=4 / 6 loci (HLA-A, B, drbl site serological matching) were matched between donors; the next was the number of cord blood CD34 +, which should be at least > 1x10^5/kg; Our center initially determined the order of cord blood selection: HLA matching > CD34 + number > blood type > gender source.

Exclusion criteria

Exclusion criteria: 1. organ dysfunction or dysfunction can not tolerate pretreatment; 2. previous allo-HSCT; 3. acquired immunodeficiency disease; 4. any significant abnormal coexisting disease or mental illness, affecting the patient's life safety and compliance, affecting informed consent, research participation, follow-up or result interpretation.

Design outcomes

Primary

MeasureTime frame
Hematopoietic reconstitution;Immune reconstruction;Stem cell implantation;Graft versus host disease;infection;Hemorrhagic cystitis;

Countries

China

Contacts

Public ContactKai Chen

Children's Hospital of Shanghai

chenk860622@163.com+86 13621904798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026